PBYI
vs
S&P 500
PBYI
S&P 500
Over the past 12 months, PBYI has significantly outperformed S&P 500, delivering a return of +76% compared to S&P 500's +20% growth.
Stocks Performance
PBYI vs S&P 500
Performance Gap
PBYI vs S&P 500
Performance By Year
PBYI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Puma Biotechnology Inc
Glance View
Puma Biotechnology is a specialty drug company that makes and sells prescription cancer medicines, with its main product being NERLYNX, an oral treatment used in certain HER2-positive breast cancer settings. It does not sell general consumer products; instead, it focuses on medicines that are prescribed by oncologists and dispensed through the healthcare system. The company makes money primarily by selling its drug to pharmacies, hospitals, and other healthcare channels that serve patients with breast cancer. Its customers are the doctors, clinics, and drug distributors that decide whether the medicine gets used, while patients and insurers are the end payers through the normal reimbursement process. What makes Puma different is that it is not a broad pharmaceutical company with many drugs in many disease areas. It is a focused oncology business built around the commercialization of a small number of targeted therapies, so its success depends heavily on physician demand, clinical adoption, and insurance coverage for its cancer treatments.
